No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
ANIP ANI Pharmaceuticals
- 64.580
- -0.900-1.37%
Close Apr 18 16:00 ET
- 63.290
- -1.290-2.00%
Post 16:56 ET
1.35BMarket Cap75.98P/E (TTM)
65.975High64.430Low184.18KVolume65.300Open65.480Pre Close12.01MTurnover1.15%Turnover Ratio75.98P/E (Static)20.98MShares70.81052wk High3.13P/B1.03BFloat Cap36.99052wk Low--Dividend TTM16.01MShs Float392.040Historical High--Div YieldTTM2.36%Amplitude4.800Historical Low65.188Avg Price1Lot Size
Post-Market
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Form 144 | ANI Pharmaceuticals(ANIP.US) Officer Proposes to Sell 677.27K in Common Stocks
SEC FILLINGS DISCLOSED/ Apr 18, $ANI Pharmaceuticals(ANIP.US)$ Officer Shanmugam Muthusamy intends to sell 10,423 shares of its common stock on Apr 18, with a total market value of approximately $677.
ANI Pharmaceuticals to Discuss First Quarter 2024 Financial Results on May 10, 2024, at 8:30 A.m. ET
BAUDETTE, Minn., April 18, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. ("ANI" or the "Company") (NASDAQ:ANIP) today announced that the Company will release its first quarter 2024 financial results on Friday, May
ANI Pharmaceuticals(ANIP.US) Officer Sells US$1.5 Million in Common Stock
$ANI Pharmaceuticals(ANIP.US)$ Officer Shanmugam Muthusamy sold 22,768 shares of common stock on Apr 15, 16, 17, 2024 at an average price of $65.91 for a total value of $1.5 million.Source: Announceme
Ani Pharmaceuticals Insider Sold Shares Worth $1,500,589, According to a Recent SEC Filing
Muthusamy Shanmugam, Director & Head, Research & Development, and COO, Novitium Operations, on April 15, 2024, sold 22,768 shares in Ani Pharmaceuticals (ANIP) for $1,500,589. Following the Form 4 fil
Form 144 | ANI Pharmaceuticals(ANIP.US) Officer Proposes to Sell 622.58K in Common Stocks
SEC FILLINGS DISCLOSED/ Apr 17, $ANI Pharmaceuticals(ANIP.US)$ Officer Shanmugam Muthusamy intends to sell 9,520 shares of its common stock on Apr 17, with a total market value of approximately $622.5
ANI Pharmaceuticals Financial Report: Key Insights Revealed
Comments
Despite last quarter's price drop, ANI Pharmaceuticals, Inc. is seen promising due to strong share price momentum. The firm's shift from loss to profitability in the past three years signals good performance and growth.
ANI Pharmaceuticals (NASDAQ:ANIP) Delivers Shareholders Respectable 19% CAGR Over 3 Years, Surging 5.9% in the Last Week AloneThe company's weak ROE, falling net income, and retention of most profits without sufficient growth may not benefit investors. Future earnings, though, are projected to grow.
ColumnsToday's pre-market stock movers: BBIO, LZB, ORA, DOW and more
Gainers:
• $La-Z-Boy(LZB.US$ +9.3% (In reaction to earnings/guidance)
• $Enanta Pharmaceuticals(ENTA.US$ +6.7% (ENTA files patent infringement lawsuit against $Pfizer(PFE.US$)
• $Ikena Oncology(IKNA.US$ +6.6% (granted Fast Track designation for IK-930)
• $BridgeBio Pharma(BBIO.US$ +6.4% (Announces Early Positive Data for BBP-812)
• $Krystal Biotech(KRYS.US$ +5% (submits Biologies License Application to FDA seeking approval of B-V...
• $La-Z-Boy(LZB.US$ +9.3% (In reaction to earnings/guidance)
• $Enanta Pharmaceuticals(ENTA.US$ +6.7% (ENTA files patent infringement lawsuit against $Pfizer(PFE.US$)
• $Ikena Oncology(IKNA.US$ +6.6% (granted Fast Track designation for IK-930)
• $BridgeBio Pharma(BBIO.US$ +6.4% (Announces Early Positive Data for BBP-812)
• $Krystal Biotech(KRYS.US$ +5% (submits Biologies License Application to FDA seeking approval of B-V...
8
1
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg